A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic.
![Thumbnail](/bitstream/handle/internal/3801/Tiu_2020_LOauthor%20manuscript_clean.pdf.jpg?sequence=35&isAllowed=y)
View/ Open
Date
2020-07-01Author
Tiu, C
Shinde, R
Yap, C
Rao Baikady, B
Banerji, U
Minchom, AR
de Bono, JS
Lopez, JS
Type
Journal Article
Metadata
Show full item recordCollections
Subject
Humans
Pneumonia, Viral
Coronavirus Infections
Neoplasms
Antiviral Agents
Risk Assessment
Clinical Trials, Phase I as Topic
Pandemics
United Kingdom
Betacoronavirus
Data Management
COVID-19
SARS-CoV-2
Research team
Medicine (de Bono Prostate)
Clinical Pharmacology – Adaptive Therapy
Clinical Trials & Statistics Unit
Prostate Cancer Targeted Therapy Group
Language
eng
Date accepted
2020-05-27
License start date
2020-07
Citation
The Lancet. Oncology, 2020, 21 (7), pp. 889 - 891
Publisher
ELSEVIER SCIENCE INC